Compounded vs Brand-Name GLP-1: What You Need to Know in 2026

What Is Compounded Semaglutide?

Compounded semaglutide is a version of the active ingredient in Ozempic and Wegovy that is mixed by a compounding pharmacy rather than manufactured by Novo Nordisk. During the semaglutide shortage (2022-2024), the FDA allowed compounding pharmacies to produce semaglutide under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounded medications are not FDA-approved. They do not undergo the same rigorous testing for safety, efficacy, and manufacturing quality as brand-name drugs. While some compounding pharmacies maintain high standards, others have been found producing medications with contamination, incorrect dosing, and unapproved ingredients.

Brand-Name GLP-1 Medications

FDA-approved GLP-1 medications for weight loss include:

• Wegovy (semaglutide injection) — Novo Nordisk, FDA-approved for chronic weight management
• Ozempic (semaglutide injection) — Novo Nordisk, FDA-approved for type 2 diabetes (commonly prescribed off-label for weight loss)
• Zepbound (tirzepatide injection) — Eli Lilly, FDA-approved for chronic weight management
• Oral Wegovy (semaglutide tablet) — Novo Nordisk, FDA-approved December 2024 for weight management

These medications are manufactured under strict FDA oversight with consistent quality controls, verified dosing accuracy, and established safety profiles from large-scale clinical trials.

Legal Status in 2026: The Shortage Is Over

In February 2025, the FDA officially declared the semaglutide shortage resolved. This has massive implications for compounding pharmacies:

• The legal basis is gone. Section 503A only permits compounding of drugs that are on the FDA shortage list. With semaglutide removed, compounders no longer have the exemption.
• 50+ warning letters sent. The FDA has issued warning letters to more than 50 compounding pharmacies, demanding they cease production of compounded semaglutide.
• Enforcement is ramping up. Some pharmacies have been ordered to recall products. The FDA has indicated it will pursue legal action against non-compliant compounders.
• Some compounders are fighting back.Legal challenges are ongoing, but the FDA's position is clear: compounding semaglutide without the shortage exemption is illegal.

Safety Concerns with Compounded GLP-1

The FDA and independent investigations have identified serious safety issues with compounded semaglutide products:

• Contaminated batches: Testing has revealed bacterial contamination, particulate matter, and impurities in compounded semaglutide vials from multiple pharmacies.
• Dosing errors: Some compounded products contained significantly more or less semaglutide than labeled — leading to either dangerous overdoses or ineffective treatment.
• Hospitalizations: The FDA has received reports of adverse events including severe gastrointestinal reactions, allergic responses, and hospitalizations linked to compounded GLP-1 products.
• No sterility guarantee: Unlike FDA-approved manufacturers, many compounders lack the rigorous sterility controls required for injectable medications.
• Lack of clinical data: Compounded formulations have not been studied in clinical trials. Their bioavailability, absorption rates, and side effect profiles may differ.

The Semaglutide Salt Form Problem

One of the most alarming discoveries in 2025-2026 is that some compounding pharmacies have been using semaglutide salt forms (such as semaglutide sodium or semaglutide acetate) rather than the base form of semaglutide used in Ozempic and Wegovy.

This is a critical distinction:

• Different active ingredient: Semaglutide salt forms are chemically different from the semaglutide in FDA-approved products. They have not been tested for safety or efficacy.
• Unknown bioavailability: The body may absorb salt forms differently, leading to unpredictable blood levels and effects.
• FDA position: The FDA has stated that semaglutide salt forms are not the same drug as semaglutide base and cannot be legally compounded as substitutes.
• Patients unaware: Most patients receiving salt-form semaglutide do not know they are getting a different compound than what they expected.